A Phase 3b, Randomized, Placebo-controlle Study Evaluating the Efficacy and Safety of Elexa-caftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Sub-jects 6 Through 11 Years of Age Who Are Hetero-zygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (VX19-445-116)

This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozy-gous for F508del and a minimal function (MF) mutation (F/MF
genotypes).